Clinical ovarian cancer and other gynecologic malignancies最新文献

筛选
英文 中文
2022-RA-209-ESGO A retrospective study of ovarian cancer among elderly – evaluation and prognosis 老年人卵巢癌的回顾性研究——评估和预后
Clinical ovarian cancer and other gynecologic malignancies Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.483
Miriam R. Brezis, S. P. Hasson, E. Shachar, D. Grisaro, I. Laskov, N. Michaan, L. Adar, Avigail Harpaz, Adi Diner, Bar Levy, I. Wolf, T. Safra
{"title":"2022-RA-209-ESGO A retrospective study of ovarian cancer among elderly – evaluation and prognosis","authors":"Miriam R. Brezis, S. P. Hasson, E. Shachar, D. Grisaro, I. Laskov, N. Michaan, L. Adar, Avigail Harpaz, Adi Diner, Bar Levy, I. Wolf, T. Safra","doi":"10.1136/ijgc-2022-esgo.483","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.483","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"130 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74117972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-VA-572-ESGO Hudson posterior exenteration, with the use of ICG fluorescence to assess rectal anastomosis and ureteral integrity 2022-VA-572-ESGO Hudson后切术,使用ICG荧光评估直肠吻合和输尿管完整性
Clinical ovarian cancer and other gynecologic malignancies Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.515
D. Nguyen, B. N. Santana, G. Babin, S. Forte, Mathilde Mairé, F. Guyon
{"title":"2022-VA-572-ESGO Hudson posterior exenteration, with the use of ICG fluorescence to assess rectal anastomosis and ureteral integrity","authors":"D. Nguyen, B. N. Santana, G. Babin, S. Forte, Mathilde Mairé, F. Guyon","doi":"10.1136/ijgc-2022-esgo.515","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.515","url":null,"abstract":"The proposed test is a viable alternative to the Myriad myChoice HRD test and can easily be implemented in a clinical laboratory for routine practice. The performance of the tests is similar in terms of hazard ratio but the lower fail-ure rate of the Geneva HRD test allows a 10% increase in the number of patients receiving a conclusive laboratory result.","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75273692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-1140-ESGO Rare ovarian tumors not a rarity anymore 罕见的卵巢肿瘤不再罕见了
Clinical ovarian cancer and other gynecologic malignancies Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.649
A. Singla, R. Aggarwal
{"title":"2022-RA-1140-ESGO Rare ovarian tumors not a rarity anymore","authors":"A. Singla, R. Aggarwal","doi":"10.1136/ijgc-2022-esgo.649","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.649","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72661173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-1607-ESGO Optimal time interval between neoadjuvant platinum-based chemotherapy and interval debulking surgery 新辅助铂基化疗与间歇减积手术的最佳时间间隔
Clinical ovarian cancer and other gynecologic malignancies Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.755
A. Andrikopoulou, K. Apostolidou, C. Theofanakis, C. Markellos, Efthymia Skafida, O. Fiste, M. Kaparelou, K. Koutsoukos, N. Thomakos, D. Haidopoulos, A. Rodolakis, F. Zagouri, M. Dimopoulos, M. Liontos
{"title":"2022-RA-1607-ESGO Optimal time interval between neoadjuvant platinum-based chemotherapy and interval debulking surgery","authors":"A. Andrikopoulou, K. Apostolidou, C. Theofanakis, C. Markellos, Efthymia Skafida, O. Fiste, M. Kaparelou, K. Koutsoukos, N. Thomakos, D. Haidopoulos, A. Rodolakis, F. Zagouri, M. Dimopoulos, M. Liontos","doi":"10.1136/ijgc-2022-esgo.755","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.755","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76480934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-1675-ESGO Development of an intra-operative disease score to predict complete cytoreduction in advanced-stage ovarian cancer by using artificial intelligence 利用人工智能开发术中疾病评分,预测晚期卵巢癌的完全细胞减少
Clinical ovarian cancer and other gynecologic malignancies Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.773
A. Laios, E. Kalampokis, R. Johnson, S. Munot, R. Hutson, A. Thangavelu, T. Broadhead, G. Theophilou, D. Nugent, D. Dejong
{"title":"2022-RA-1675-ESGO Development of an intra-operative disease score to predict complete cytoreduction in advanced-stage ovarian cancer by using artificial intelligence","authors":"A. Laios, E. Kalampokis, R. Johnson, S. Munot, R. Hutson, A. Thangavelu, T. Broadhead, G. Theophilou, D. Nugent, D. Dejong","doi":"10.1136/ijgc-2022-esgo.773","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.773","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"511 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80086545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary perito 2022-RA-1540-ESGO MITO 25.1:一项随机,分子驱动的II期试验,根据HRD状态选择卡铂-紫杉醇-贝伐单抗vs卡铂-紫杉醇-贝伐单抗-鲁卡帕尼,用于晚期(III期B-C-IV期)卵巢原发性围期患者
Clinical ovarian cancer and other gynecologic malignancies Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.739
L. Musacchio, V. Salutari, S. Pignata, G. Valabrega, L. Zavallone, G. Cormio, A. Mosconi, S. Giolitto, E. Giudice, C. Ricci, C. Zamagni, C. Nero, M. V. Carbone, V. Ghizzoni, R. Sorio, S. Siena, F. Tronconi, A. Savarese, G. Scambia, D. Lorusso
{"title":"2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary perito","authors":"L. Musacchio, V. Salutari, S. Pignata, G. Valabrega, L. Zavallone, G. Cormio, A. Mosconi, S. Giolitto, E. Giudice, C. Ricci, C. Zamagni, C. Nero, M. V. Carbone, V. Ghizzoni, R. Sorio, S. Siena, F. Tronconi, A. Savarese, G. Scambia, D. Lorusso","doi":"10.1136/ijgc-2022-esgo.739","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.739","url":null,"abstract":"Introduction/Background The discrimination of borderline ovarian tumor (BOT) is challenging Ultrasonography (US) is the most essential imaging modality for distinguishing ovarian masses but depends on the experience of radiologists. In 2014, the IOTA group carried out the assessment of different neoplasia’s in the Adnex Model. It was used to discriminate benign, BOTs, stage I, stage II-IV invasive ovarian cancer, and secondary metastatic cancer. This study aims to evaluate the efficacy of the Adnex model in the determination of BOTs. Methodology This was a retrospective study, medical records of histopathologically proven cases of BOTs were included from the year 2009 to 2021. The ultrasound and clinical findings were entered in an online Adnex calculator. These results were used to calculate the absolute risk predicting the probability of mass being as BOT. Results A total of 22 cases of BOT were included. Efficacy in terms of sensitivity of the Adnex model for preoperative diagnosis of BOTs was 18.2% [95%CI: 7.31–38.52]. Performance of the Adnex model based on absolute risk (AR) improves with a selection of a more inclusive cut-off value, varying from 4.5% (1/22) correctly classified case of BOT with the cut-off 20%,18.2% (4/22) with the cut-off 10% and up to 55.5% (12/22) classified cases of BOT with cut off value of 3%. Similarly, relative risk (RR)was also used to classify the BOT, but only 4(18.2%) cases were identified correctly. Conclusion More encompassing cut-off values allow the model to differentiate BOTs better. The calculation based on RR or AR with a cut-off value of at least 10% should be used when evaluating BOTs.The IOTA Adnex model did not perform well in predicting cases of BOTs that were histopathologically proven in terms of sensitivity.","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81693959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-1101-ESGO Prediction of incomplete cytoreduction in primary debulking surgery of advanced stage ovarian cancer patients: Usefulness of the entire peritoneal cancer index (PCI) versus exclusive assessment of small intestine/mesentery/hepatoduodenal ligament carcinosis 预测晚期卵巢癌患者原发性降压手术中不完全细胞减少:整个腹膜癌指数(PCI)与小肠/肠系膜/肝十二指肠韧带癌的单独评估的有效性
Clinical ovarian cancer and other gynecologic malignancies Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.634
Clara E Goerdt, D. Bokhua, V. Auletta, A. Kather, I. Runnebaum
{"title":"2022-RA-1101-ESGO Prediction of incomplete cytoreduction in primary debulking surgery of advanced stage ovarian cancer patients: Usefulness of the entire peritoneal cancer index (PCI) versus exclusive assessment of small intestine/mesentery/hepatoduodenal ligament carcinosis","authors":"Clara E Goerdt, D. Bokhua, V. Auletta, A. Kather, I. Runnebaum","doi":"10.1136/ijgc-2022-esgo.634","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.634","url":null,"abstract":"may be useful radiological markers of poor prognosis to support clinical decision-making when considering HPN","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84267948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-1515-ESGO Impact of surgical staging on survival of low grade endometrioid ovarian cancer apparently confined to the ovary 手术分期对明显局限于卵巢的低级别子宫内膜样卵巢癌生存的影响
Clinical ovarian cancer and other gynecologic malignancies Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.733
N. Bizzarri, M. Imterat, R. Fruscio, A. Perrone, R. Mancari, A. Traut, A. Rosati, A. Bois, D. Ferrari, P. De Iaco, R. Ergasti, B. Ataseven, S. Volonte’, M. Tesei, M. Perri, F. Heitz, N. Concin, F. Fanfani, E. Vizza, G. Scambia, P. Harter, A. Fagotti
{"title":"2022-RA-1515-ESGO Impact of surgical staging on survival of low grade endometrioid ovarian cancer apparently confined to the ovary","authors":"N. Bizzarri, M. Imterat, R. Fruscio, A. Perrone, R. Mancari, A. Traut, A. Rosati, A. Bois, D. Ferrari, P. De Iaco, R. Ergasti, B. Ataseven, S. Volonte’, M. Tesei, M. Perri, F. Heitz, N. Concin, F. Fanfani, E. Vizza, G. Scambia, P. Harter, A. Fagotti","doi":"10.1136/ijgc-2022-esgo.733","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.733","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85877033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-1112-ESGO MFAP5 is related to ovarian cancer progression but not suitable as prognostic biomarker 2022-RA-1112-ESGO MFAP5与卵巢癌进展相关,但不适合作为预后生物标志物
Clinical ovarian cancer and other gynecologic malignancies Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.641
K. Kujawa, E. Zembala-Nożyńska, J. Syrkis, A. Cortez, J. Kupryjańczyk, K. Lisowska
{"title":"2022-RA-1112-ESGO MFAP5 is related to ovarian cancer progression but not suitable as prognostic biomarker","authors":"K. Kujawa, E. Zembala-Nożyńska, J. Syrkis, A. Cortez, J. Kupryjańczyk, K. Lisowska","doi":"10.1136/ijgc-2022-esgo.641","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.641","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76899731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2022-RA-1565-ESGO Pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for metastatic ovarian cancer, fallopian tube cancer and primary peritoneal carcinoma: a systematic review by the UK PIPAC collaborative 加压腹腔雾化化疗(PIPAC)治疗转移性卵巢癌、输卵管癌和原发性腹膜癌:英国PIPAC合作项目的系统综述
Clinical ovarian cancer and other gynecologic malignancies Pub Date : 2022-10-01 DOI: 10.1136/ijgc-2022-esgo.747
Adam Naskretski, Susan Prosser, G. Owens, S. Jones
{"title":"2022-RA-1565-ESGO Pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for metastatic ovarian cancer, fallopian tube cancer and primary peritoneal carcinoma: a systematic review by the UK PIPAC collaborative","authors":"Adam Naskretski, Susan Prosser, G. Owens, S. Jones","doi":"10.1136/ijgc-2022-esgo.747","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.747","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77044116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信